Overview Dividends

(SIGA) SIGA Technologies - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8269171067

Antiviral, Smallpox, TPOXX, Health Security

SIGA EPS (Earnings per Share)

EPS (Earnings per Share) of SIGA over the last years for every Quarter: "2020-09": 0.31, "2020-12": 0.26, "2021-03": -0.02, "2021-06": -0.0034, "2021-09": -0.04, "2021-12": 0.98, "2022-03": -0.01, "2022-06": 0.03, "2022-09": 0.45, "2022-12": -0.01, "2023-03": -0.01, "2023-06": -0.04, "2023-09": -0.01, "2023-12": 1.0164, "2024-03": 0.1436, "2024-06": 0.0255, "2024-09": 0.0187, "2024-12": 0.6409, "2025-03": -0.0057, "2025-06": 0.49, "2025-09": -0.0889,
EPS Growth (3Y CAGR): -69.02%
EPS Trend (3Y Correlation): 16.2%

SIGA Revenue

Revenue of SIGA over the last years for every Quarter: 2020-09: 44.261407, 2020-12: 37.729355, 2021-03: 4.813744, 2021-06: 8.653289, 2021-09: 4.846172, 2021-12: 115.357248, 2022-03: 10.539299, 2022-06: 16.667045, 2022-09: 72.211127, 2022-12: 11.358139, 2023-03: 8.323025, 2023-06: 5.878166, 2023-09: 9.235171, 2023-12: 116.480859, 2024-03: 25.429855, 2024-06: 21.810891, 2024-09: 10.009781, 2024-12: 81.468823, 2025-03: 7.040815, 2025-06: 81.120004, 2025-09: 2.62,
Revenue Growth (3Y CAGR): -41.34%
Revenue Trend (3Y Correlation): 9.5%
Risk via 10d forecast
Volatility 60.7%
Value at Risk 5%th 89.3%
Relative Tail Risk -10.56%
Reward TTM
Sharpe Ratio 0.19
Alpha -17.01
Character TTM
Hurst Exponent 0.531
Beta 0.684
Beta Downside 0.451
Drawdowns 3y
Max DD 56.39%
Mean DD 33.98%
Median DD 37.72%

Description: SIGA SIGA Technologies October 24, 2025

SIGA Technologies, Inc. (NASDAQ:SIGA) is a commercial-stage biopharma focused on the U.S. health-security market, best known for its FDA-approved antiviral TPOXX, the only licensed treatment for smallpox.

Key metrics as of the latest filing (Q2 2024): cash and short-term investments of roughly $140 million, a net loss of $32 million for the trailing twelve months, and a market-cap near $350 million. The company’s revenue is driven almost entirely by government contracts for TPOXX, which together with the broader biodefense budget (projected to grow at ~4% CAGR) constitute its primary economic driver.

Sector trends that affect SIGA include heightened federal spending on pandemic preparedness and the expanding “health-security” niche, which has attracted increased R&D incentives and potential partnership opportunities with defense contractors.

For a deeper, data-rich analysis of SIGA’s valuation and peer landscape, you may find ValueRay’s research tools helpful.

SIGA Stock Overview

Market Cap in USD 435m
Sub-Industry Pharmaceuticals
IPO / Inception 1997-09-09
Return 12m vs S&P 500 -7.28%
Analyst Rating -

SIGA Dividends

Dividend Yield 10.00%
Yield on Cost 5y 10.62%
Yield CAGR 5y 15.47%
Payout Consistency 98.8%
Payout Ratio 57.9%

SIGA Growth Ratios

CAGR 3y -5.54%
CAGR/Max DD Calmar Ratio -0.10
CAGR/Mean DD Pain Ratio -0.16
Current Volume 543.9k
Average Volume 337.4k

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (74.5m TTM) > 0 and > 6% of Revenue (6% = 10.3m TTM)
FCFTA 0.50 (>2.0%) and ΔFCFTA 13.63pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 117.8% (prev 91.17%; Δ 26.63pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.50 (>3.0%) and CFO 116.6m > Net Income 74.5m (YES >=105%, WARN >=100%)
Net Debt (-171.0m) to EBITDA (94.3m) ratio: -1.81 <= 3.0 (WARN <= 3.5)
Current Ratio 9.17 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (71.6m) change vs 12m ago -0.23% (target <= -2.0% for YES)
Gross Margin 76.29% (prev 78.34%; Δ -2.05pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 80.69% (prev 88.93%; Δ -8.24pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -29.47 (EBITDA TTM 94.3m / Interest Expense TTM -3.18m) >= 6 (WARN >= 3)

Altman Z'' 6.76

(A) 0.88 = (Total Current Assets 227.7m - Total Current Liabilities 24.8m) / Total Assets 231.6m
(B) -0.16 = Retained Earnings (Balance) -37.6m / Total Assets 231.6m
(C) 0.44 = EBIT TTM 93.7m / Avg Total Assets 213.5m
(D) -1.34 = Book Value of Equity -37.6m / Total Liabilities 28.1m
Total Rating: 6.76 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 83.53

1. Piotroski 4.50pt = -0.50
2. FCF Yield 44.00% = 5.0
3. FCF Margin 67.52% = 7.50
4. Debt/Equity 0.00 = 2.50
5. Debt/Ebitda -1.81 = 2.50
6. ROIC - WACC (= 25.30)% = 12.50
7. RoE 35.26% = 2.50
8. Rev. Trend 9.54% = 0.72
9. EPS Trend 16.22% = 0.81

What is the price of SIGA shares?

As of November 17, 2025, the stock is trading at USD 6.00 with a total of 543,900 shares traded.
Over the past week, the price has changed by -7.83%, over one month by -28.14%, over three months by -32.74% and over the past year by +7.22%.

Is SIGA Technologies a good stock to buy?

Yes, based on ValueRay´s Fundamental Analyses, SIGA Technologies (NASDAQ:SIGA) is currently (November 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 83.53 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SIGA is around 5.44 USD . This means that SIGA is currently overvalued and has a potential downside of -9.33%.

Is SIGA a buy, sell or hold?

SIGA Technologies has no consensus analysts rating.

What are the forecasts/targets for the SIGA price?

Issuer Target Up/Down from current
Wallstreet Target Price 17.5 192.2%
Analysts Target Price 17.5 192.2%
ValueRay Target Price 6.1 1.2%

SIGA Fundamental Data Overview November 16, 2025

Market Cap USD = 435.4m (435.4m USD * 1.0 USD.USD)
P/E Trailing = 5.8252
P/E Forward = 3.8241
P/S = 2.5277
P/B = 2.1398
Beta = 0.972
Revenue TTM = 172.2m USD
EBIT TTM = 93.7m USD
EBITDA TTM = 94.3m USD
Long Term Debt = 582.7k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 582.7k USD (from shortTermDebt, last quarter)
Debt = 914.5k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -171.0m USD (from netDebt column, last quarter)
Enterprise Value = 264.4m USD (435.4m + Debt 914.5k - CCE 172.0m)
Interest Coverage Ratio = -29.47 (Ebit TTM 93.7m / Interest Expense TTM -3.18m)
FCF Yield = 44.00% (FCF TTM 116.3m / Enterprise Value 264.4m)
FCF Margin = 67.52% (FCF TTM 116.3m / Revenue TTM 172.2m)
Net Margin = 43.23% (Net Income TTM 74.5m / Revenue TTM 172.2m)
Gross Margin = 76.29% ((Revenue TTM 172.2m - Cost of Revenue TTM 40.8m) / Revenue TTM)
Gross Margin QoQ = 61.75% (prev 68.50%)
Tobins Q-Ratio = 1.14 (Enterprise Value 264.4m / Total Assets 231.6m)
Interest Expense / Debt = 97.38% (Interest Expense 890.6k / Debt 914.5k)
Taxrate = 23.82% (-1.99m / -8.36m)
NOPAT = 71.4m (EBIT 93.7m * (1 - 23.82%))
Current Ratio = 9.17 (Total Current Assets 227.7m / Total Current Liabilities 24.8m)
Debt / Equity = 0.00 (Debt 914.5k / totalStockholderEquity, last quarter 203.5m)
Debt / EBITDA = -1.81 (Net Debt -171.0m / EBITDA 94.3m)
Debt / FCF = -1.47 (Net Debt -171.0m / FCF TTM 116.3m)
Total Stockholder Equity = 211.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 32.15% (Net Income 74.5m / Total Assets 231.6m)
RoE = 35.26% (Net Income TTM 74.5m / Total Stockholder Equity 211.2m)
RoCE = 44.27% (EBIT 93.7m / Capital Employed (Equity 211.2m + L.T.Debt 582.7k))
RoIC = 33.82% (NOPAT 71.4m / Invested Capital 211.2m)
WACC = 8.52% (E(435.4m)/V(436.3m) * Re(8.54%) + (debt cost/tax rate unavailable))
Discount Rate = 8.54% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -1.36%
[DCF Debug] Terminal Value 79.85% ; FCFE base≈98.4m ; Y1≈121.4m ; Y5≈207.1m
Fair Price DCF = 44.69 (DCF Value 3.20b / Shares Outstanding 71.6m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 16.22 | EPS CAGR: -69.02% | SUE: -0.51 | # QB: 0
Revenue Correlation: 9.54 | Revenue CAGR: -41.34% | SUE: 0.44 | # QB: 0

Additional Sources for SIGA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle